-continued

KVTSTIIVIQVTSTTEDTTTSSKITPKATTLAPKVMTATKTTTTQETIN

KLEETTAIPKDTATHSKVTTPKPKKPTKAPRKPTSTKKPKTPRKRKPKT

TPIPPKITTPTTPKSNPTTLAEAMLQTTTSPNQTPNSAMIEVNPKNEDA

DAAEGEKPLVILRPHVLTPIVIPGPDFLVRGPNLGIGINPMLSDETNLC

NGKPVDGLTTLRNGTLVAFRGHYFWMLRPFSPPSPPRRITEVWGIPSPI

DTVFTRCNCEGKTFFFKDSQYWRFTNDIKDAGYPKLISKGFGGLSGKIV

AALSIATYKNRPESVYFFKRGGRIQQYIYKQEPIRKCPGRRPAIHYSVY

GEAPQIRRRRFERAIGPSQTHTIRIHYSPVRVSYQDKVPSTDFLHNEVK

VSTLWRGLPDTVTSAISLPNLRKPDGYDYYAFSKDQYYNIDVPSRTARA

ITTRSGQTLSKVWYNCP.

10. The recombinant lubricin of claim **9**, wherein the repeated sequence is KEPAPTTP (SEQ ID NO:1).

11. The recombinant lubricin of claim **4**, further comprising a secretory signal that is optionally MAWKTLPIYLLLLLSVFVIQQVSS (SEQ ID NO:72).

12. The recombinant lubricin of claim **5**, further comprising a secretory signal that is METDTLLLWVLLLWVPGSTGD (SEQ ID NO:81).

13. The recombinant lubricin of claim **6**, further comprising a secretory signal that is METDTLLLWVLLLWVPGSTGD (SEQ ID NO:81).

14. The recombinant lubricin of claim **7**, further comprising a secretory signal that is MQWKILPIYLLLLSVFLIQQVSS (SEQ ID NO:82).

15. The recombinant lubricin of claim **8**, further comprising a secretory signal that is MQWKILPIYLLLLSVFLIQQVSS (SEQ ID NO:82).

16. The recombinant lubricin of claim **9**, further comprising a secretory signal that is MEWKILPIYLLLLLSIFSIQEVSS (SEQ ID NO:74).

17. The recombinant lubricin of claim **10**, further comprising a secretory sequence that is MEWKILPIYLLLLLSIFSIQEVSS (SEQ ID NO:74).

18. The recombinant lubricin of claim **1**, wherein the recombinant lubricin has an intra-articular half-life when injected into a mammal of more than 4 days.

19. The recombinant lubricin of claim **17**, wherein the recombinant lubricin has an intra-articular half-life when injected into a mammal of at least 15 days.

20. The recombinant lubricin of claim **19**, wherein the recombinant lubricin has an intra-articular half-life when injected into a mammal of at least 30 days.

21. A composition comprising a recombinant lubricin of claim **1**.

22. The composition of claim **21**, wherein the composition is selected from a pharmaceutical formulation, an eye drop, and a contact lens solution.

23. The composition of claim **22**, for use in treating a human in need thereof.

24. The composition of claim **22**, for use in treating a non-human mammal in need thereof.

25. The composition of claim **24**, wherein the composition is for use in treating a canine or equine animal in need thereof.

26. One or more mammalian cells comprising a recombinant lubricin of claim **1**.

27. The one or more mammalian cells of claim **26**, wherein the cells are in a suspension culture.

28. An isolated polynucleotide and/or an expression vector encoding a recombinant lubricin of claim **1**.

29. One or more mammalian cells comprising the isolated polynucleotide of claim **28**, wherein the one or more mammalian cells are optionally adapted to growth in a suspension culture.

30. A suspension culture comprising mammalian cells that express a recombinant lubricin of claim **1**.

31. A method of making a recombinant lubricin of claim **1**, the method comprising introducing into mammalian cells a polynucleotide encoding said recombinant lubricin such that the cells express said recombinant lubricin.

32. The method of claim **31**, further comprising isolated the recombinant lubricin from the mammalian cells.

33. An inanimate article fully or partially coated with a composition comprising a recombinant lubricin of claim **1**.

34. The inanimate article of claim **33**, wherein the inanimate article comprises a contact lens.

35. A method for treating an individual in need thereof, the method comprising introducing into the individual a composition comprising a recombinant lubricin of claim **1**.

36. The method of claim **35**, wherein the recombinant lubricin persists in the individual for a period of greater than four days.

37. The method of claim **36**, wherein the recombinant lubricin persists in the individual for a period of greater than 30 days.

38. The method of claim **37**, wherein the recombinant lubricin persists in the individual for a period of at least 30 days.

39. The method of claim **35**, wherein the individual is in need of treatment for a disorder of a synovial joint, a tendon sheath, or bursa.

40. The method of claim **39**, comprising introducing the composition into the synovial joint.

41. The method of claim **35**, wherein the individual is in need of treatment for a disorder of the eye.

42. The method of claim **41**, comprising introducing the composition into the eye of the individual.

43. The method of claim **35**, wherein the individual is in need of treatment for a disorder of a mucosal surface.

44. The method of claim **43**, wherein the composition is contacted with the mucosal surface.

* * * * *